therapeutic mirna delivery suppresses tumorigenesis in a murine liver cancer model janaiah kota,1...
TRANSCRIPT
![Page 1: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/1.jpg)
Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A. Wentzel,2 Chrystal
LMontgomery,1Hun-Way Hwang,2 Tsung-Cheng Chang,2 Perumal Vivekanandan,5 Michael
Torbenson,5 K. Reed Clark,1,7Jerry R. Mendell,1,7,8,* and Joshua T. Mendell2,4,6,*
1Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, OH
43205, USA
2The McKusick-Nathans Institute of Genetic Medicine
3The High Throughput Biology Center
4Department of Molecular Biology and Genetics
5Department of Pathology
6Department of Pediatrics
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
7Department of Pediatrics
8Department of Neurology
The Ohio State University, Columbus, OH 43210, USA
Cell 137, 1005–1017, 2009
![Page 2: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/2.jpg)
Cell 137, 1005–1017, 2009
![Page 3: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/3.jpg)
microRNA-Regulators of our genome
www.microrna.ic.cz/obr/image003.png
![Page 4: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/4.jpg)
miRNA and Cancer
All examined tumor types
Abnormal miRNA expression patterns
• miRNA profiles Tumor classification
Prognosis
Response to therapy
• Functional Studies Potent pro- and anti- tumorigenic activity of
specific miRNA both in-vitro and in-vivo.
![Page 5: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/5.jpg)
miRNA based Cancer Therapeutics
Two Approaches
Inhibition of oncogenic miRNA
Replacement of tumor suppressor miRNA
![Page 6: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/6.jpg)
Progress In The Field
• Anti-sense mediated inhibition of oncogenic miRNAs (Love et al.,2008; Stenvang et al.,2008).
• Global miRNA repression enhances cellular transformation and tumorigenesis in both in vitro and in vivo models (Kumar et al., 2007)
• Myc activation in B cell lymphoma leads to widespread miRNA repression. (Mendel & Chang et.al)
• Enforced expression of these specific miRNAs dramatically suppresses lymphomagenesis.
• Re-expression of even a single miRNA could provide significant anti-cancer therapeutics.
• Viral delivery of let-7 miRNA ( Tumour Suppressor ) suppressed tumor growth in a mouse model of adenocarcenoma (Esquela-Kerscher et al., 2008; Kumar et al., 2008) .
![Page 7: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/7.jpg)
• let-7 directly targets KRAS,( an Oncogene) the initiating oncogene in this tumor model.
• Thus, the utility of miRNA therapeutics in situations where they do not target the initiating oncogene remains to be studied.
![Page 8: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/8.jpg)
HYPOTHESIS
• miRNAs can be directly used as general anticancer therapeutics even when they do not target the initiating oncogene.
• REASONING: The most therapeutically useful miRNAs would be expressed at low levels in tumors but would be highly expressed in
normal tissues.
![Page 9: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/9.jpg)
Selection of Therapeutic miRNA
Along with mouse,miR-26a expressed at lower levels in human HCC.
![Page 10: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/10.jpg)
Therapeutic Potential of miR-26a
• INITIAL TEST:- MSCV derived retroviral construct to enforce expression of miR-26a in HepG2 (Hepatocarcinoma Cell Lines) cells.
![Page 11: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/11.jpg)
• Cell cycle profiles- PI staining and Flow Cytometry
Cell cycle profiles after Nocodazole treatment
miR26a expression induces G1 arrest in Human Liver Cancer Cells
![Page 12: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/12.jpg)
miR-26a Directly Represses Expression of Cyclins D2 and E2
• Predicted targets of miR-26a examined by Targetscan algorithm.
Cyclin E1, cyclin E2, cyclin D2 and CDK6
Required in G1-S transition
![Page 13: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/13.jpg)
Verification of direct regulation of transcripts by miR-26a
• Reporter plasmids with predicted binding sites cloned downstream of
luciferase ORF.
![Page 14: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/14.jpg)
MYC is Not a Target of miR-26a
• Potent therapeutic role of miR-26a proved in vitro.
• Can systemic delivery of miR-26a be used as a therapeutic strategy for this tumor type in vivo?
• First confirmed that miR-26a does not regulate MYC itself.
• MYC not a predicted target of miR-26a by common algorithms –Targetscan, miRanda and PicTar.
• Western blotting confirms retroviral expression of miR-26a in HepG2 cells doesn’t affect MYC protein abundance.
![Page 15: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/15.jpg)
AAV Vector System to express miR-26a and eGFP• CONSTRUCTS
![Page 16: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/16.jpg)
VECTOR DELIVERY
• Single tail-vein injection.
• Liver tissue harvested after 3 weeks: >90% Transduction.
• Previous study-AAV mediated delivery of shRNA induced
acute liver toxicity probably due to inhibition of
miRNA pathway.
![Page 17: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/17.jpg)
Suppression of Tumorigenesis by miR-26a
• Timeline:-
6/8 8/10
2/10 treated mice- aggressive tumor- lower transduction efficiency
Technical failure rather than resistance to miR-26a therapeutics.
![Page 18: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/18.jpg)
EFFECT ON PROLIFERATION AND TUMOR-SPECIFIC APOPTOSIS
CELLULAR PROLIFERATION-
Ki67 staining
TUMOR-SPECIFIC APOPTOSIS-
TUNEL staining
![Page 19: Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A](https://reader035.vdocuments.us/reader035/viewer/2022081514/56649f285503460f94c406fe/html5/thumbnails/19.jpg)
Thank You